MICIN

MICIN operates commercial telemedicine services ("curon"), provides digital solutions supporting decentralized clinical trials—including Japan’s first fully remote online oncology drug trial—and develops digital therapeutics. The company also offers insurance products tailored to healthcare needs.[1][2][3] No traditional drug development or molecule-based clinical results are reported. MICIN is a leading Japanese digital health startup founded in late 2015 by physician Seigo Hara. It specializes in providing commercial-grade telemedicine services (“curon”), developing digital therapeutic applications aimed at improving medication adherence/self-care, enabling decentralized and fully virtual clinical trials through proprietary platforms—including electronic consent—and offering innovative insurance products tailored to the evolving needs of patients engaging with modern healthcare systems. Its work has included landmark collaborations enabling the first completely remote interventional cancer drug study conducted entirely online within Japan’s regulatory environment. The firm remains privately held with significant backing from investors like Mitsubishi Corporation and continues expanding its impact across the intersection of medicine, informatics, patient engagement technologies, and insurtech within Asia’s rapidly digitizing healthcare landscape.[1][2][3]